<info type="ChemicalEntity">Debrisoquine</info> phenotype and the pharmacokinetics and <info type="GeneOrGeneProduct">beta-2 receptor</info> pharmacodynamics of <info type="ChemicalEntity">metoprolol</info> and its enantiomers.

The metabolism of the cardioselective <info type="ChemicalEntity">beta-blocker metoprolol</info> is under genetic control of the <info type="ChemicalEntity">debrisoquine/sparteine</info> type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher <info type="GeneOrGeneProduct">beta-1 adrenoceptor</info> antagonistic potency of <info type="ChemicalEntity">racemic metoprolol</info> in <info type="OrganismTaxon">EMs</info>. We investigated if the latter also applies to the <info type="GeneOrGeneProduct">beta-2 adrenoceptor</info> antagonism by <info type="ChemicalEntity">metoprolol</info>. The drug effect studied was the antagonism by <info type="ChemicalEntity">metoprolol</info> of <info type="ChemicalEntity">terbutaline</info>-induced <info type="DiseaseOrPhenotypicFeature">hypokalemia</info>. By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of <info type="ChemicalEntity">racemic metoprolol</info> and the active <info type="ChemicalEntity">S-isomer</info>, were quantitated in <info type="OrganismTaxon">EMs</info> and <info type="OrganismTaxon">PMs</info> in terms of <info type="ChemicalEntity">IC50</info> values, representing <info type="ChemicalEntity">metoprolol</info> plasma concentrations resulting in half-maximum receptor occupancy. Six <info type="OrganismTaxon">EMs</info> received 0.5 mg of <info type="ChemicalEntity">terbutaline</info> s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of <info type="ChemicalEntity">metoprolol</info> p.o. Five <info type="OrganismTaxon">PMs</info> were studied according to the same protocol, except for a higher <info type="ChemicalEntity">terbutaline</info> dose (0.75 mg) on day 2. Blood samples for the analysis of plasma potassium, <info type="ChemicalEntity">terbutaline</info>, <info type="ChemicalEntity">metoprolol</info> (<info type="ChemicalEntity">racemic</info>, <info type="ChemicalEntity">R-</info> and <info type="ChemicalEntity">S-isomer</info>), and <info type="ChemicalEntity">alpha-hydroxymetoprolol</info> concentrations were taken at regular time intervals, during 8 hr after <info type="ChemicalEntity">metoprolol</info>. In <info type="OrganismTaxon">PMs</info>, <info type="ChemicalEntity">metoprolol</info> increased the <info type="ChemicalEntity">terbutaline</info> area under the plasma concentration vs. time curve (+67%). Higher <info type="ChemicalEntity">metoprolol</info>/<info type="ChemicalEntity">alpha-hydroxymetoprolol</info> ratios in <info type="OrganismTaxon">PMs</info> were predictive for higher <info type="ChemicalEntity">R-/S-isomer</info> ratios of unchanged drug. There was a difference in <info type="ChemicalEntity">metoprolol</info> potency with higher <info type="ChemicalEntity">racemic metoprolol</info> <info type="ChemicalEntity">IC50</info> values in <info type="OrganismTaxon">PMs</info> (72 +/- 7 ng.ml-1) than <info type="OrganismTaxon">EMs</info> (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)